$888M Crypto Pivot: Nasdaq Biotech Firm Goes All-In on HYPE Token with Bold Treasury Bet

Key Takeaways:

• Sonnet BioTherapeutics announces a $888 million merger to launch a public HYPE token reserve.
• The new entity, Hyperliquid Strategies Inc (HSI), aims to be the largest U.S.-listed holder of HYPE.
• Major crypto investors like Paradigm, Galaxy Digital, and Pantera Capital are backing the deal.

In an unprecedented turn for a Nasdaq-listed biotech company, Sonnet BioTherapeutics has pivoted into crypto, unveiling plans for an $888 million business combination to build one of the largest HYPE token treasuries in the United States. This move marks a significant crossover between traditional finance, public equity, and the blockchain sector.

Sonnet BioTherapeutics (NASDAQ: SONN), previously focused on oncology biotech, announced on July 14 that it had signed a definitive agreement with Rorschach I LLC, a crypto-focused entity formed by affiliates of Atlas Merchant Capital and Paradigm Operations LP. The transaction will result in the formation of Hyperliquid Strategies Inc. (HSI), a publicly traded crypto treasury company focused on HYPE, the native token of the Hyperliquid Layer-1 blockchain.

Under the terms of the deal:

• HSI will hold 12.6 million HYPE tokens, worth around $583 million.
• It will also receive $305 million in cash, giving the new entity a total value of $888 million at closing.
• HSI will remain listed on Nasdaq under a new ticker, becoming one of the largest public holders of HYPE globally.

This marks one of the most aggressive crypto treasury moves by a publicly listed U.S. company since MicroStrategy’s pivot to Bitcoin.

Read More: Hyperliquid Review 2025; Is This Crypto Exchange Safe or a Scam?

The transaction is backed by a powerhouse of institutional investors including Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital. These players bring extensive crypto experience, signaling high confidence in both the Hyperliquid ecosystem and the long-term value of HYPE.

Hyperliquid is an emerging Layer-1 blockchain known for its high-throughput on-chain trading infrastructure. It features two core components:

• HyperCore, which powers on-chain perpetual futures and supports up to 200,000 orders per second.
• HyperEVM, a general-purpose smart contract platform that extends HyperCore’s liquidity to dApps and developers.

The network’s consensus mechanism, HyperBFT, facilitates its speed and scalability, and forms part of the technology advantage against established chains.

Featuring on Forbes’ list of the top 20 largest cryptocurrencies by market cap (as of July 6), HYPE is currently the 13th-largest, status that few, even in the industry, could have predicted. The token isn’t accessible; U.S. investors won’t be able to buy it easily, which is where HSI sees an opportunity — to offer indirect exposure through equity markets.

Upon closing, HSI will be led by industry veterans:

• Bob Diamond, Co-founder and CEO of Atlas Merchant Capital, will serve as Chairman.
• David Schamis, also of Atlas, will become CEO of HSI.
• Eric Rosengren, former President of the Boston Federal Reserve, will join the board, alongside two independent directors from Sonnet.

The team aims to turn HSI into a leading model for crypto-native treasury management in the public markets. A Sponsor Advisory Agreement (SAA) will be established with Rorschach to integrate HYPE into long-term treasury strategy.

This approach is similar to the strategy deployed by MicroStrategy with Bitcoin, but with a different token and infrastructure in focus.

Matt Huang, Co-founder of Paradigm, stated that Hyperliquid has “broken out” as a protocol with strong fundamentals, citing:

• High product quality
• A rapidly growing community
• Technical capabilities that rival Ethereum

The fact that HYPE is scarce, in contrast to solid US investor demand, offers the HSI’s setup an attractive framework as a public equity proxy for tokens.

As crypto embarks on a new market cycle and institutional involvement continues to increase, the timing appears to be a strategic one. Spot ETF approvals, overall regulatory clarity and post-halving dynamics are influencing the revival in confidence in the market.

Interestingly, Sonnet’s legacy biotech operations will continue under the HSI umbrella as a wholly owned subsidiary. The company will retain focus on its clinical pipeline, including SON-1010, while disposing of other non-core assets.

To support this transition:

• Sonnet raised $5.5 million via private placement of convertible preferred shares and warrants.
• $2 million in convertible notes will be converted at the time of the transaction.
• A Contingent Value Right (CVR) will be issued to shareholders tied to the biotech assets.

This structure provides investors with direct exposure to the crypto pivot, while retaining the potential upside from Sonnet’s oncology programs that are currently underway.

The post $888M Crypto Pivot: Nasdaq Biotech Firm Goes All-In on HYPE Token with Bold Treasury Bet appeared first on CryptoNinjas.